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Hypertension  is associated  with  well  known  structural  and functional  alterations  in  both  resistance  and
conduit  arteries,  which  may  be  the  result  from  long-lasting  high  blood  pressure  and  may  also  be the
cause  of  maintained  hypertension  and  its complications.  Therefore,  in  addition  to lowering  blood  pres-
sure, therapeutic  strategies  targeting  the  structural  and  functional  modiﬁcations  found  in  hypertensive
patients  may  prevent  the  cardiovascular  events  and  decrease  the  death  rates  associated  with  hyperten-
sion.  Mounting  evidence  indicates  that  many  vascular  alterations  associated  with  sustained  hypertension
are  due  to imbalanced  matrix  metalloproteinases  (MMPs),  a family  of  zinc-endopeptidases  that  degrade
not  only  proteins  of extracellular  matrix  (ECM)  but several  other  substrates.  Recent  observations  showed
that abnormal  MMP  activity  is  a feature  of the pathogenesis  of  hypertension  and  other  diseases,  thus  justi-
fying  the  development  of  drugs  aiming  at MMP  downregulation.  This  review  focuses  on  the  extracellular
actions  of MMPs  in hypertension-induced  chronic  vascular  alterations.  We  then  discuss  the  effects  of
MMP inhibitors,  especially  doxycycline,  on  the vascular  changes  associated  with  hypertension.  There
is  now  strong  evidence  that  MMP  inhibition  with  doxycycline  (and  maybe  other  MMP inhibitors)  may
attenuate  the  functional  and  structural  alterations  associated  with  hypertension,  including  increases  in
arterial stiffness.  These  beneﬁcial  effects  may  be,  at least  in part, independent  of  their  antihypertensive
effects.© 2011 Elsevier Ltd.   
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. Introduction Blood Pressure, more than 1 billion of people have hypertension
Open access under the Elsevier OA license.Hypertension is one of the main public health problems in the
orld and is associated with increased morbidity and mortality.
ccording to the Seventh Report of the Joint National Commit-
ee on Prevention, Detection, Evaluation and Treatment of High
∗ Corresponding author. Tel.: +55 16 36024014; fax: +55 16 36024102.
E-mail addresses: rfgerlach@forp.usp.br, rfgerlach@yahoo.com (R.F. Gerlach).
043-6618 © 2011 Elsevier Ltd     .  
oi:10.1016/j.phrs.2011.04.002
Open access under the Elsevier OA license.and approximately 7.1 million of deaths per year are a consequence
of it. This disease is considered a strong risk factor for the develop-
ment of other cardiovascular diseases with many deaths resulting
from heart failure and stroke [1].
Hypertension is associated with well known structural and func-
tional alterations in both resistance and conduit arteries, which
may  result from long-lasting high blood pressure and may  also be
the cause of maintained hypertension and its complications [2–6].
Therefore, in addition to lowering blood pressure, therapeutic
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trategies targeting the structural and functional modiﬁcations
ound in hypertensive patients may  prevent the cardiovascular
vents and decrease the death rates associated with hypertension.
Mounting evidence indicates that many vascular alterations
ssociated with sustained hypertension are due to imbalanced
atrix metalloproteinases (MMPs) [5,7,8],  a family of zinc-
ndopeptidases, ﬁrst discovered for their ability to degrade several
roteins of extracellular matrix (ECM) [9,10].  These recent obser-
ations showing that abnormal MMP  activity is a key feature of
he pathogenesis of hypertension (and other diseases) [11–13]
ave justiﬁed the development of drugs aiming at MMPs  down-
egulation. Although other important mechanisms are clearly
nvolved in the maladaptive vascular alterations of hypertension,
uch as activated renin–angiotensin–aldosterone pathway and
ncreased oxidative stress, it is now becoming evident that MMPs
ct as important downstream mediators, thus promoting vascular
emodeling and functional alterations [14–18].
In this review we will focus on the extracellular actions of MMPs
n hypertension-induced chronic vascular alterations. We  then dis-
uss the effects of MMP  inhibitors, especially doxycycline, on the
ascular changes associated with hypertension.
. MMPs  and their regulation
MMPs are a group of zinc-dependent endopeptidases that
egrade a variety of components of extra-cellular matrix (ECM).
heir activities in the vascular tissues contribute to vascular remod-
ling associated with cardiovascular diseases. While other MMPs
ay  be relevant, we will focus on MMP-2 and MMP-9 (gelatinases
 and B, respectively) because these two enzymes play key roles
n the pathogenic mechanisms underlying the vascular alterations
ssociated with hypertension [5,7,8].  Structurally, the catalytic
omains of gelatinases differ from those found in other MMPs
ecause they contain three ﬁbronectin type II-like domains, which
onfer speciﬁcity to cleave denatured collagen (gelatin) and colla-
en type IV. They also have a signaling peptide at the N-terminus
hat is responsible for their transport out of the cells, a hinge region,
nd a haemopexin-like C terminal domain. Several excellent arti-
les provide detailed information on the structure and relevant
iochemistry of MMPs  [10,19–22].
All MMPs  are initially synthesized as inactive ‘pro-MMPs’ that
ventually become fully active. MMPs  are regulated at multiple
evels including gene transcription, post-translational activation,
nd by interaction with their endogenous inhibitors, the tissue
nhibitors of metalloproteinases (TIMPs) [22]. Although four known
embers of the TIMP family (TIMP-1, -2, -3, and -4) have already
een described in the vascular wall, TIMP-1 and -2 are the best
haracterized in hypertensive animals and humans [23,24]. Acti-
ation of pro-MMPs involves the disruption of a coordination
etween a thiol group in their propeptide and a Zn2+ present in
he active site of the catalytic domain [25]. Interestingly, MMPs
ay activate other MMPs  and act synergistically. For example,
roteolysis of the propeptide domain of MMP-2 by membrane type-
MP-1 (MT-MMP-1; MMP-14) occurs extracellularly and leads
o complete removal of the propeptide region, thus resulting in
 smaller, 64 kDa, active MMP-2 form [21,22]. Moreover, recent
tudies showed that the 72 kDa zymogen form of MMP-2 is also
ctivated by peroxynitrite and glutathione, thus leading to confor-
ational changes in the enzyme by disrupting the coordination
etween the cysteine thiol group and Zn2+ [26,27].  This activation
esults in the active MMP-2, as reported in conditions associated
ith increased oxidative stress [28]. Such a pathogenic mech-
nism involving oxidative stress-induced MMP-2 activation has
een implicated in two kidney-one clip (2K-1C) hypertension [17].
onsistent with these ﬁndings, antioxidant drugs attenuated vascu- Research 64 (2011) 567– 572
lar MMP-2 activity and protected against the vascular dysfunction
and remodeling found in 2K-1C hypertension [17].
3. Involvement of MMP-2 and -9 in the vascular
remodeling associated with hypertension
Although vascular remodeling in hypertension may  initially
be adaptive so as to normalize vascular wall stress in response
to increased intravascular pressure, it may  become maladaptive
and lead to vascular dysfunction [29]. Signiﬁcant differences exist
when the vascular remodeling of the resistance, small arteries
is compared with that found in large, conduit arteries. While
hypertension leads to increased media thickness, reduced inter-
nal and external diameters, and increased media thickness/lumen
(M/L) ratio (inward eutrophic remodeling) in the small vessels,
large vessel remodeling consists of wall hypertrophy character-
ized by increased media thickness without changes in arterial
lumen [29,30]. Both types of vascular remodeling involve degra-
dation and reorganization of the ECM scaffold, and hypertrophy
or hyperplasia of vascular smooth muscle cells (VSMCs), thus con-
tributing to thickened vessel wall and vascular stiffness [2–5]. These
vascular structural changes maintain high blood pressure and
contribute to the development of complications associated with
hypertension.
Increased circulating and tissue MMP-2 and MMP-9 levels
have been reported in clinical hypertension and in animal models
[23,31–37]. Because MMPs  can degrade a variety of components
of ECM, it is now becoming clear that imbalanced MMPs  activi-
ties play an important role in hypertensive vascular remodeling.
However, a recent study suggested that MMP-9 exerts a beneﬁ-
cial role early on in angiotensin-II-induced hypertension because
increased vascular stiffness and increased pulse pressure were
found in hypertensive MMP-9 knock-out mice [31]. Conversely,
sustained hypertension upregulates MMPs  and leads to excessive
ECM degradation, VSMCs proliferation and migration, and vascular
hypertrophy [2,38].  Therefore, it is possible that temporal changes
may  exist in MMPs  levels during the development of hypertension,
which may  be involved in the initial beneﬁcial adaptive vascular
remodeling that is followed by hypertrophic/eutrophic maladap-
tive remodeling.
MMPs  activities may  disrupt the interactions of ECM compo-
nents with VSMCs, thus promoting new cells-matrix interactions,
and VSMCs change from an inactive phenotype to cells that migrate
and proliferate [39–43] (Fig. 1). These cellular changes lead to
increased synthesis of ECM components and promote vessel wall
thickening and increased vascular stiffness [40]. Integrin-mediated
intracellular mechanisms are involved in this maladaptive struc-
tural vascular alterations [2,44,45], with upregulated MMP-2 and
MMP-9 being consistently implicated, both in early and in late
hypertrophic vascular remodeling associated with hypertension
in patients and in animal models [23,31,32,34–36]. In addition,
we have recently found evidence suggesting that increased vas-
cular MMP-2 levels may  cause vascular functional alterations [36].
Indeed, we  found increased MMP-2 levels associated with impaired
endothelial-dependent vasorelaxation, arterial wall hypertrophy,
and excessive collagen and elastin deposition in the aortas from
2K-1C hypertensive rats [36]. Since these recent ﬁndings implicate
MMPs  in hypertension-induced vascular remodeling and dysfunc-
tion, MMPs  inhibition became an attractive therapeutic aim in
the treatment and/or prevention of such disease and its compli-
cations. While there are several effective antihypertensive drugs
that have been widely used in the therapy of hypertension and
its cardiovascular complications, controlling MMPs activities with
MMPs  inhibitors could help to prevent the clinical consequences of
hypertension.
M.M. Castro et al. / Pharmacological Research 64 (2011) 567– 572 569
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dig. 1. MMPs  affect the interactions of extracellular matrix components with vas
igrate and proliferate. Doxycycline may  prevent these alterations and protect aga
.1. Doxycycline protects against the structural vascular
lterations associated with hypertension
Doxycycline acts at low doses to inhibit MMPs, both in clinical
nd in experimental conditions. In fact, this drug is a surprisingly
otent MMP  inhibitor, and it has been shown to inhibit MMP  activi-
ies at plasma concentrations well below those required to produce
ntimicrobial effects [46], as demonstrated in several disease mod-
ls [47–51].  While this tetracycline inhibits MMP  activities by
inding directly to MMP’s zinc ion domains, thus altering their
nteractions with substrates [52,53], it can also downregulate the
ranscription of MMPs  mRNA [54].
Recent studies by our group showed that doxycycline com-
letely prevented the maladaptive vascular alterations associated
ith increased MMP-2 levels in experimental 2K-1C hyperten-
ion [36,55]. Hypertensive rats were treated with doxycycline
30 mg/kg/day by gavage) for 8 weeks after hypertension had been
stablished. Lower increases in systolic blood pressure (SBP) were
een in doxycycline-treated 2K-1C rats when compared with 2K-1C
ontrols treated with vehicle, thus indicating that treatment with
oxycycline attenuated the increases in SBP, at least in part. More-
ver, doxycycline blunted the increases in aortic MMP-2 activity
ound in hypertensive rats, and this effect was associated with
revention of vascular hypertrophic remodeling (Fig. 1). Inter-
stingly, while doxycycline attenuated 2K-1C-induced increases
n SBP by approximately 40%, this tetracycline completely pre-
ented hypertension-induced increases in aortic media thickness,
edia/lumen ratio and cross sectional area, as well as the increases
n vascular collagen and elastin contents [36]. The fact that doxycy-
line only partially attenuated 2K-1C hypertension and completely
revented the structural alterations usually found in this model
f hypertension suggests that inhibiting MMPs  activities blunts the
evelopment of structural vascular changes associated with hyper-mooth muscle cells, which may change from an inactive phenotype to cells that
ascular structural modiﬁcations associated with hypertension.
tension, independently of the antihypertensive effects produced by
this drug. However, it remains to be tested whether MMP  inhibi-
tion may  prevent the cardiovascular alterations found in clinical
hypertension.
While previous studies are consistent with the idea that
enhanced MMP-2 activity is critically involved in hypertensive
maladaptive vascular remodeling of large arteries [36,55], another
study suggested that signiﬁcant differences may  exist between
large and small arteries [34]. Interestingly, while progressive
increases in MMP-2 levels and activity were associated with
hypertrophic remodeling of large arteries from rats with N-nitro-
l-arginine methyl ester (l-NAME)-induced hypertension, only
transient increases in MMP-2 activity were found in parallel with
vascular remodeling in small (mesenteric) arteries [34]. Notwith-
standing the fact that doxycycline signiﬁcantly inhibited MMP-2
upregulation and MMP-2 activity in both small and large arteries,
this drug prevented aortic hypertrophic remodeling without exert-
ing signiﬁcant effects on mesenteric eutrophic remodeling [34],
thus suggesting that doxycycline may  not prevent small vessels
hypertensive remodeling.
In addition to MMP-2 inhibition, the protective effects exerted
by doxycycline against the vascular changes associated with hyper-
tension may be a result of inhibition of other MMPs. In fact,
treatment with doxycycline was  associated with attenuation of
2K-1C hypertension-induced increases in MMP-2, MMP-9, and
MMP-14 levels, whereas no signiﬁcant alterations in aortic TIMP-
1, -2, -3, and -4 levels were found in this study [55], although
increasing TIMP/MMP  ratio could downregulate MMP  activity.
While MMP-14 is important for MMP-2 activation, MMP-14 activity
has also been implicated in cell migration and invasion [56], thus
possibly contributing to hypertrophic remodeling. In that study,
we found enhanced MMP-9 levels mainly in the aortic intima
layer from 2K-1C rats, whereas MMP-2 and -14 were more clearly
570 M.M. Castro et al. / Pharmacological Research 64 (2011) 567– 572
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cig. 2. Representative photomicrographs of the immunohistochemical localization 
2K-1C)  hypertensive rats treated with doxycycline 30 mg/kg/day (or vehicle) for 8
nduced increases in aortic MMP-2, MMP-9, and MMP-14 levels.
ound in the aortic middle layer, in close interaction with VSMCs
Fig. 2) [55]. These observations suggest that these MMPs may  con-
ribute to both intimal thickening and medial VSMCs hypertrophy.
reatment with doxycycline completely prevented these structural
ascular alterations in hypertensive rats (Fig. 2) [55]. In line with
hese ﬁndings, comparatively lower vascular MMP-9 than MMP-
 expression levels were also reported in DOCA-salt hypertensive
ats [23], and MMP-9 appears to have a much more restricted tissue
istribution, being mainly localized in the intima layer [56].
Inhibition of MMP-mediated vascular changes in 2K-1C hyper-
ension by doxycycline is dose-dependent [57]. Given the
mportance of using subantimicrobial doses of doxycycline, the
ffects of three different doses of doxycycline (3, 10, and 30 mg/kg)
n the vascular changes associated with 2K-1C hypertension were
ompared. Treatment with doxycycline at 30 mg/kg/day, but not
ith 3 or 10 mg/kg/day, decreased MMPs  levels and gelatinolytic
ctivity, and blunted the vascular alterations found in 2K-1C hyper-
ensive rats [57]. These ﬁndings may  be especially important when
onsidering the possible side effects associated with doxycycline.
hile there is concern about the emergence of doxycycline-
esistant bacteria, these ﬁnding suggest that beneﬁcial effects may
e lost if this drug is used at low doses [57]. However, the deﬁnition
f this narrow dose range requires additional studies, and signiﬁ-
ant differences may  exist when animal models are compared with
linical diseases. For example, doxycycline at doses escalating from
0 up to 100 mg  per day presumably inhibited smooth muscle cell
roliferation in association with a reduction in urinary MMP-2 and
MP-9 in a fatal lung disease, lymphangioleiomyomatosis, and
liminated the need for lung transplant [58]. Therefore, further
tudies are required to determine the doses that should be used
n different conditions.
.2. Doxycycline protects against the functional vascular
lterations associated with hypertension
In addition to the protection against the structural modiﬁ-
ations associated with hypertension, as discussed above, thereP-2, MMP-14, and MMP-9 in aortas from Sham-operated and two-kidney, one-clip
s. It is noteworthy that doxycycline signiﬁcantly attenuated 2K-1C hypertension-
is now growing evidence that MMP  inhibition with doxycycline
also protects against functional vascular alterations associated
with hypertension. Supporting this suggestion, there is mount-
ing evidence that enhanced MMP-2 activity impairs vasodilation
and promotes vasoconstriction, thereby contributing to increased
vascular resistance in hypertension. Indeed, MMP-2 may pro-
mote the vasoconstrictor effects of big endothelin-1 (ET-1) by
cleaving this peptide to a potent vasoconstrictor, ET-1-32 [59].
MMP-2 also cleaves the vasodilatory CGRP (calcitonin gene-related
peptide) [60] and adrenomedullin [61], thereby promoting vaso-
constriction. Therefore, it is possible that MMP  inhibition with
doxycycline restores vasodilation by inhibiting MMPs. In line with
this suggestion, we found that doxycycline reversed the impaired,
Ach-induced, endothelium-dependent responses found in 2K-1C
rats [36]. Moreover, doxycycline produced similar improvements
of endocardial endothelial response to acetylcholine [62]. While
the improved responses to acetylcholine may  be due to MMP-2
downregulation, MMP-9 inhibition by doxycycline may also con-
tribute to the improved endothelium-dependent responses. This
is because increased vasodilatory responses to acetylcholine were
reported in MMP-9 knockout mice [63]. These observations high-
light the notion that MMPs  degrade a variety of non-ECM substrates
[64], including 2-adrenergic receptors [65], which cause vasodi-
lation. Curiously, lead exposure has been associated with MMPs
upregulation [66] and hypertension, and doxycycline prevented
lead-induced vascular MMPs  activation and hypertension [67].
4. MMP  inhibition may  prevent arterial stiffness
An important consequence of long-term increases in MMP  activ-
ity and hypertension-induced structural changes in large arteries
is increased arterial stiffness. This alteration reduces vessel com-
pliance and distensibility, thus resulting in ampliﬁcation of the
arterial pulse pressure and pulse wave velocity (PWV), a marker
of arterial stiffness [68]. MMP-mediated excessive degradation
of arterial elastin [69,70] and re-synthesis of collagen (the stiff
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rotein) [40] leads to increased arterial stiffness and ﬁbrosis. More-
ver, part of elastin that is re-synthesized after its degradation is
ess efﬁcient and this change underlies the loss of arterial wall
esilience [70]. Interestingly, products of elastic ﬁber degradation
ffect VSMC migration and proliferation [70]. MMPs  also mediate
ore deposition of proteoglycans and ﬁbronectin in the vascula-
ure during hypertension, thus contributing to the increased vessel
tiffness [71,72].  Indeed, clinical studies with hypertensive patients
howed that increased plasma MMP-9 activity correlates positively
ith PWV  in patients with isolated systolic hypertension, thus sug-
esting an MMP-9 participation in the development of this disease
32].
In line with these ideas, some studies suggest that aortic medial
alciﬁcation may  contribute to the development of aortic stiff-
ess in hypertension [7],  and MMP-9 may  be involved in this
rocess [69]. Using an animal model of arterial elastocalcinosis,
t was shown that early arterial MMP-9 activation could induce
oth gradual elastin degradation and activation of transforming
rowth factor  (TGF-) [69]. These alterations were associated
ith progressive increases in aortic medial calcium deposition
nd also long-lasting elastin fragmentation, thus contributing
o increased aortic PWV  and to the development of hyperten-
ion [69]. Importantly, treatment with doxycycline (30 mg/kg/day)
revented aortic calciﬁcation and increases in aortic PWV, thus sug-
esting MMP-9 is a key player in aortic medial calciﬁcation and
ncreased stiffness of hypertension [69].
Taken together, these recent studies strongly suggest that MMPs
nhibition with doxycycline may  attenuate functional alterations
ssociated with hypertension, including the increases in arterial
tiffness.
. Concluding remarks
It is now becoming clear that MMPs  play relevant roles in
he pathogenic mechanisms involved in the vascular alterations
f hypertension, and the recent ﬁndings discussed in this review
re consistent with the idea that inhibiting MMPs  with doxycy-
line may  offer improved cardiovascular protection to hypertensive
atients. It is also possible that doxycycline may  prevent the dele-
erious effects associated with other conditions that upregulate
MPs and are linked to cardiovascular diseases, such as peri-
dontal disease [73,74]. In line with this conclusion, it is possible
hat some antihypertensive drugs that reduce arterial blood pres-
ure and downregulate MMPs  [15,17,75,76] may  provide additional
ardiovascular protection to that associated with their direct anti-
ypertensive effects. However, the use of subantimicrobial doses
f doxycycline combined with antihypertensive drugs may  offer
reater advantages in the pharmacological therapy of hyperten-
ive patients. These suggestions warrant clinical studies to validate
hem. It should be noted that outstanding clinical trials have clearly
hown that treatment with subantimicrobial doses of doxycycline
ay  exert anti-inﬂammatory effects and protect against relevant
ardiovascular events [77,78].
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